Cas:852445-83-1 [1,3-bis[2,6-di(propan-2-yl)phenyl]imidazol-2-ylidene]-chlorogold manufacturer & supplier

Chemical Name:[1,3-bis[2,6-di(propan-2-yl)phenyl]imidazol-2-ylidene]-chlorogold

CAS.NO:852445-83-1

Synonyms:Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]gold(I);(1,3-Bis(2,6-diisopropylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene)(chloro)gold;1,3-Bis(2,6-diisopropylphenyl-imidazol-2-ylidene)gold(I) chloride

Molecular Formula:C₂₇H₃₆AuClN₂

Molecular Weight:621.00800

HS Code:

Physical and Chemical Properties:

Melting point:298ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:27.03000

Exact Mass:620.22300

LogP:5.02620

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]gold(I) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-Bis(2,6-diisopropylphenyl-imidazol-2-ylidene)gold(I) chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-Bis(2,6-diisopropylphenyl-imidazol-2-ylidene)gold(I) chloride Use and application,1,3-Bis(2,6-diisopropylphenyl-imidazol-2-ylidene)gold(I) chloride technical grade,usp/ep/jp grade.

Related News: Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. N-(2,6-difluorophenyl)-N-(pyridin-3-ylmethyl)cyclopropanecarboxamide manufacturers Biocatalysis is widely recognized to be one of the most powerful tools for organic synthesis due to its green credentials and its exquisite regio-, enantio-, and stereoselectivities. (S)-7-methyl-1-oxo-2,3,4,5,6,7-hexahydroindene suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. (+-)-3-methyl-3-(4′-phenylbenzoyl)-1-cyclopentanone vendor & factory.